Beard SM, McCrink L, Le TK, Garcia-Cebrian A, Monz B, Malik RA. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin. 2008 Feb;24(2):385-99.
Edin HM, DiBenedetti D, Hill CD. Adherence among patients with Parkinson's Disease taking ropinirole immediate release at least three times daily. Poster presented at the Movement Disorders Society; June 13, 2008. [abstract] Mov Disord. 2008; 23:S344-5.
Doward L, Karim S, Ramanna G, Petit T, Burns A. Development of the Dementia Quality of Life questionnaire (D-QOL): uK version. Aging Ment Health. 2008 Jan;12(1):144-8.
Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007 Oct 1;23(10):2517-29.
Yood MU, Lafata JE, Koro C, Wells KE, Pladevall-Vila M. Time to pharmacotherapy change in response to elevated HbA(1c) test results. Curr Med Res Opin. 2006 Aug;22(8):1567-74.
Portenoy R, ID Pain Steering Committee, McLeod LD. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin. 2006;22(8):1555-65.
Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004 Jan 1;20(12):1883-93. doi: 10.1185/030079904X11510.
Hagell P, Whalley D, McKenna SP, Lindvall 0. Health status measurement in Parkinson's disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord. 2003 Jul 1;18(7):773-83.